The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles

Berberine (BBR) hydrochloride is a traditional Chinese medicine with unique hypoglycemic and lipid-lowering effects discovered in recent years. The combination of BBR with other hypoglycemic drugs and lipid-lowering drugs could become a promising treatment strategy. With the aim of evaluating the po...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guofei Li, Mingming Zhao, Limei Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Validation DDI Berberine hydrochloride Hypoglycemic drugs Lipid-lowering drugs Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/24aeca21ebfd4983ae8e9efb1e32ff5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24aeca21ebfd4983ae8e9efb1e32ff5f
record_format	dspace
spelling	oai:doaj.org-article:24aeca21ebfd4983ae8e9efb1e32ff5f2021-11-28T04:29:36ZThe drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles1878-535210.1016/j.arabjc.2021.103562https://doaj.org/article/24aeca21ebfd4983ae8e9efb1e32ff5f2022-02-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1878535221005773https://doaj.org/toc/1878-5352Berberine (BBR) hydrochloride is a traditional Chinese medicine with unique hypoglycemic and lipid-lowering effects discovered in recent years. The combination of BBR with other hypoglycemic drugs and lipid-lowering drugs could become a promising treatment strategy. With the aim of evaluating the potential drug-drug interaction (DDI) based on the pharmacokinetics between BBR and simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles, an UPLC-MS/MS method has been developed and validated. The analytes and internal standards were extracted from plasma samples using a magnetic solid phase extraction technique, and then separated by a Luna® Omega C18 column (20.0 × 2.0 mm, 1.6 μm) with water containing 3 mM ammonium and 0.1% formic acid and acetonitrile containing 3 mM ammonium and 0.1% formic acid as the mobile phase. Validation of the UPLC-MS/MS method was carried out following the criteria of the Chinese Pharmacopeia, mainly including specificity, carryover, calibration curve, crosstalk, precision, accuracy, dilution integrity, matrix effect, recovery and stability. The results showed that all the criteria of the method validation met the Chinese Pharmacopoeia guidelines, and the proposed UPLC-MS/MS method was proven to be sensitive, simple and specific to determine all the analytes in the beagles’ plasma samples simultaneously. Meanwhile, the potential DDI between BBR and simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin was confirmed in this paper, especially for simvastatin, fenofibrate, gemfibrozil and glimepiride.Guofei LiMingming ZhaoLimei ZhaoElsevierarticleValidationDDIBerberine hydrochlorideHypoglycemic drugsLipid-lowering drugsChemistryQD1-999ENArabian Journal of Chemistry, Vol 15, Iss 2, Pp 103562- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Validation DDI Berberine hydrochloride Hypoglycemic drugs Lipid-lowering drugs Chemistry QD1-999
spellingShingle	Validation DDI Berberine hydrochloride Hypoglycemic drugs Lipid-lowering drugs Chemistry QD1-999 Guofei Li Mingming Zhao Limei Zhao The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
description	Berberine (BBR) hydrochloride is a traditional Chinese medicine with unique hypoglycemic and lipid-lowering effects discovered in recent years. The combination of BBR with other hypoglycemic drugs and lipid-lowering drugs could become a promising treatment strategy. With the aim of evaluating the potential drug-drug interaction (DDI) based on the pharmacokinetics between BBR and simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles, an UPLC-MS/MS method has been developed and validated. The analytes and internal standards were extracted from plasma samples using a magnetic solid phase extraction technique, and then separated by a Luna® Omega C18 column (20.0 × 2.0 mm, 1.6 μm) with water containing 3 mM ammonium and 0.1% formic acid and acetonitrile containing 3 mM ammonium and 0.1% formic acid as the mobile phase. Validation of the UPLC-MS/MS method was carried out following the criteria of the Chinese Pharmacopeia, mainly including specificity, carryover, calibration curve, crosstalk, precision, accuracy, dilution integrity, matrix effect, recovery and stability. The results showed that all the criteria of the method validation met the Chinese Pharmacopoeia guidelines, and the proposed UPLC-MS/MS method was proven to be sensitive, simple and specific to determine all the analytes in the beagles’ plasma samples simultaneously. Meanwhile, the potential DDI between BBR and simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin was confirmed in this paper, especially for simvastatin, fenofibrate, gemfibrozil and glimepiride.
format	article
author	Guofei Li Mingming Zhao Limei Zhao
author_facet	Guofei Li Mingming Zhao Limei Zhao
author_sort	Guofei Li
title	The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
title_short	The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
title_full	The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
title_fullStr	The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
title_full_unstemmed	The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
title_sort	drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/24aeca21ebfd4983ae8e9efb1e32ff5f
work_keys_str_mv	AT guofeili thedruginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles AT mingmingzhao thedruginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles AT limeizhao thedruginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles AT guofeili druginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles AT mingmingzhao druginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles AT limeizhao druginteractionpotentialofberberinehydrochloridewhencoadministeredwithsimvastatinfenofibrategemfibrozilmetforminglimepiridenateglinidepioglitazoneandsitagliptininbeagles
_version_	1718408365289242624

The drug interaction potential of berberine hydrochloride when co-administered with simvastatin, fenofibrate, gemfibrozil, metformin, glimepiride, nateglinide, pioglitazone and sitagliptin in beagles

Ejemplares similares